PLXP
Income statement / Annual
Last year (2021), PLx Pharma Inc.'s total revenue was $8.21 M,
an increase of 26,873.38% from the previous year.
In 2021, PLx Pharma Inc.'s net income was -$51.46 M.
See PLx Pharma Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$8.21 M
|
$30,430.00
|
$565,464.00
|
$753,108.00
|
$778,657.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4.81 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$3.40 M |
$30,430.00 |
$565,464.00 |
$753,108.00 |
$778,657.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.41 |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$4.18 M
|
$4.34 M
|
$4.74 M
|
$3.92 M
|
$4.16 M
|
$12.75 M
|
$11.29 M
|
$8.90 M
|
$1.73 M
|
$844,630.00
|
| General & Administrative
Expenses |
$0.00
|
$9.15 M
|
$10.03 M
|
$7.79 M
|
$10.17 M
|
$8.61 M
|
$7.48 M
|
$4.68 M
|
$2.28 M
|
$999,356.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$40.01 M
|
$9.15 M
|
$10.03 M
|
$7.79 M
|
$10.17 M
|
$8.61 M
|
$7.48 M
|
$4.68 M
|
$2.28 M
|
$999,356.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.29 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$44.19 M |
$13.49 M |
$14.77 M |
$11.71 M |
$14.33 M |
$21.37 M |
$18.76 M |
$13.58 M |
$4.01 M |
$1.84 M |
| Cost And Expenses |
$49.00 M |
$13.49 M |
$14.77 M |
$11.71 M |
$14.33 M |
$21.37 M |
$18.76 M |
$13.58 M |
$4.01 M |
$1.84 M |
| Interest Income |
$0.00 |
$0.00 |
$405,239.00 |
$297,800.00 |
$112,377.00 |
$46,769.00 |
$22,057.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1,000.00 |
$307,950.00 |
$994,979.00 |
$1.15 M |
$1.16 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$5.55 M
|
$415,614.00
|
$405,239.00
|
$200,957.00
|
$746,008.00
|
$46,769.00
|
$22,057.00
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$35.24 M
|
-$13.46 M
|
-$13.80 M
|
$2.24 M
|
-$15.10 M
|
-$21.32 M
|
-$18.74 M
|
-$13.58 M
|
-$4.01 M
|
-$1.84 M
|
| EBITDA Ratio |
-4.29 |
-442.3 |
-24.4 |
2.98 |
-19.39 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-4.97
|
-442.3
|
-25.12
|
-14.55
|
-20.35
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$5.34 M
|
-$1.75 M
|
-$6.30 M
|
$11.86 M
|
-$418,889.00
|
$46,769.00
|
$22,057.00
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$46.13 M |
-$15.21 M |
-$20.50 M |
$896,480.00 |
-$16.27 M |
-$21.32 M |
-$18.74 M |
-$13.58 M |
-$4.01 M |
-$1.84 M |
| Income Before Tax Ratio
|
-5.62
|
-499.86
|
-36.26
|
1.19
|
-20.89
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$5.34 M |
-$107,664.00 |
$836,726.00 |
$13.00 M |
-$920,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$51.46 M |
-$15.10 M |
-$21.34 M |
$896,480.00 |
-$15.35 M |
-$21.32 M |
-$18.74 M |
-$13.58 M |
-$4.01 M |
-$1.84 M |
| Net Income Ratio |
-6.27 |
-496.32 |
-37.74 |
1.19 |
-19.71 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.18 |
-1.55 |
-2.39 |
0.1 |
-2.19 |
-16.45 |
-15.9 |
-13.84 |
-6.94 |
-3.64 |
| EPS Diluted |
-2.18 |
-1.55 |
-2.39 |
0.1 |
-2.19 |
-16.45 |
-15.9 |
-13.84 |
-6.94 |
-3.64 |
| Weighted Average Shares
Out |
$23.65 M
|
$9.71 M
|
$8.92 M
|
$8.73 M
|
$7.02 M
|
$1.30 M
|
$1.18 M
|
$981,293.00
|
$577,982.00
|
$507,035.00
|
| Weighted Average Shares
Out Diluted |
$23.65 M
|
$9.71 M
|
$8.92 M
|
$8.73 M
|
$7.02 M
|
$1.30 M
|
$1.18 M
|
$981,293.00
|
$577,982.00
|
$507,035.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
